Abstract 1204TiP
Background
Patients (pts) with extensive-stage (ES) SCLC or extra-pulmonary grade 3 (G3) NEC rapidly develop progressive disease after 1st -line cytotoxic chemotherapy, and efficacious 2nd -line treatment options are needed. Lysine Specific Demethylase 1 (LSD1, aka KDM1A) is involved in repressing transcription by removing methyl groups from mono- and di-methylated lysine 4 of histone 3, epigenetic hallmarks commonly associated with actively transcribed genes. LSD1 over-expression is associated with tumor progression and worse prognosis, and its inhibition reduces cancer cell growth, migration, and invasion. The epigenetic drug iadademstat (aka ORY-1001 or iada) is a highly potent and selective LSD1 inhibitor (LSD1i) in phase 2 clinical development for malignant indications. Iada and other LSD1is are effective in in vitro and in vivo models of SCLC by preventing INSM1 recruitment of LSD1 which results in NOTCH signaling activation, reduced NE differentiation and tumor growth inhibition. Additionally, LSD1is have been implicated in reversing chemoresistance, synergizing with paclitaxel, and enhancing immunostimulatory responses by increasing MHC-Class I expression, IFN-Type I responses and T-cell infiltration and activity.
Trial design
NCT05420636 is a multi-center, non-randomized phase II study to treat up to 42 pts with iada (150 mg oral, 5d on-2d off every week) and paclitaxel (80 mg/m2 IV weekly) in 21 day cycles. Eligibility includes adult pts with metastatic/unresectable SCLC (cohort 1) or extra pulmonary G3 NEC or metastatic/unresectable prostate or bladder cancer with G3 NE or small cell component (cohort 2), who have received 1 to 3 prior lines of therapy and progressed on or after platinum-based chemotherapy. Pts must have measurable disease, normal organ, and marrow function, stable brain mets, ECOG status ≤1 and not have received prior taxanes for metastatic disease. The primary endpoint is ORR per RECIST 1.1; secondary endpoints include rate of ≥ grade 3 toxicities, PFS, OS and DoR. Exploratory endpoints include host inflammatory cytokine and immune profile, and epigenomic and genomic analysis of tumor and peripheral blood samples.
Clinical trial identification
NCT05420636.
Editorial acknowledgement
Legal entity responsible for the study
Fox Chase Cancer Center.
Funding
Oryzon.
Disclosure
N. Vijayvergia: Non-Financial Interests, Institutional, Local PI: BMS, ITM; Financial Interests, Personal, Advisory Board: Taiho, ITM; Non-Financial Interests, Institutional, Principal Investigator: Oryzon, Puma; Non-Financial Interests, Personal, Advisory Role: Rayze Bio. P. Ghatalia: Non-Financial Interests, Institutional, Research Funding: BMS, Oryzon, Merck. D. Faller: Financial Interests, Personal, Full or part-time Employment: Oryzon. A. Limon: Financial Interests, Personal, Full or part-time Employment: Oryzon. H.P. Soares: Financial Interests, Personal, Advisory Board: Tersera, Ipsen, AstraZeneca, Novartis, ITM. J. whetstine: Financial Interests, Institutional, Research Funding: Oryzon, Salarius Pharma; Financial Interests, Personal, Advisory Board: QSonica, Vyne Therapeutics, Daiichi Sankyo, Lily Asia Ventures. H. Borghaei: Financial Interests, Personal, Advisory Board: BMS, Genentech, Eli-Lilly, Merck, EMD-serono, AstraZeneca, Novartis, Genmab, Regeneron, Amgen, Takeda, PharmaMar, Jazz Pharma, Mirati, Daiichi, Guardant, Natera, Oncocyte, BeiGene, iTeo, Boehringer Ingelheim, Puma, BerGenbio, Janssen; Financial Interests, Personal, Other, Training discussion: Pfizer; Financial Interests, Personal, Other, DSMB: Novartis; Financial Interests, Institutional, Other, Clinical trial support: BMS, Amgen; Financial Interests, Personal, Stocks/Shares, Options for scientific advisory role: Sonnetbio; Financial Interests, Personal, Stocks/Shares, Options for scientific advisory board: Nucleai, Inspira (Rgenix); Financial Interests, Institutional, Trial Chair, Investigator initiated trial support: BMS; Financial Interests, Institutional, Coordinating PI, Investigator initiated trial support: Amgen, Lilly; Financial Interests, Personal and Institutional, Trial Chair, Chair steering committee: Miratti; Financial Interests, Personal and Institutional, Steering Committee Member: Amgen, AstraZeneca; Financial Interests, Personal, Steering Committee Member, Also trial support: BMS; Other, Other, DSMB: Novartis, Takeda, Incyte, Springworks. All other authors have declared no conflicts of interest.
Resources from the same session
1203P - Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
Presenter: Tomoyuki Satake
Session: Poster session 14
1212P - Predictive value of a near-term prediction model for severe irAEs in cancer treatment with ICIs
Presenter: Jun Zhao
Session: Poster session 14
1213P - HRD complete: A novel NGS assay for detecting homologous recombination repair (HRR) gene alterations in prostate cancer
Presenter: Xin Ye
Session: Poster session 14
1214P - A novel machine learning based method to detect homozygous deletion of homologous recombination repair (HRR) genes in prostate cancer
Presenter: Jianqing Wang
Session: Poster session 14
1215P - Comparative analysis of cfDNA liquid biopsy and tumor-based next-generation sequencing (NGS) approaches
Presenter: Anastasiya Yudina
Session: Poster session 14
1216P - A spectroscopic liquid biopsy for the earlier detection of multiple cancer types
Presenter: Matthew Baker
Session: Poster session 14
1217P - Clinical evaluation of a CE-IVD liquid biopsy pan cancer genomic profiling test
Presenter: Timothy Crook
Session: Poster session 14
1218P - Exploring cancer care pathways in seven European countries: Identifying obstacles and opportunities for the role of artificial intelligence
Presenter: Shereen Nabhani
Session: Poster session 14
1219P - Artificial intelligence-based breast cancer detection facilitates automated prognosis marker assessment using multiplex fluorescence immunohistochemistry
Presenter: Tim Mandelkow
Session: Poster session 14